Aurobindo Pharma's growth story spans Europe, the US, and multiple verticals.
In Europe, the Indian generics manufacturer has a presence in the UK and nine EU markets, and it is one of the high-growth regions.
Aurobindo's Europe business CEO Venugopalan Muralidharan told the Indian television channel ET Now that the company has steadily increased its portfolio breadth.
The teams understand the diverse European market archetypes, and they are 'very much tuned' to the markets they are operating in, he added.
Muralidharan said Aurobindo started as a plain vanilla generics drug manufacturer, but it now offers a wider range of products, including biosimilars, injectables, and inhalers.
The portfolio is supported by in-house development and in-licensing.
As for biosimilars, Aurobindo recently got three approvals through the European Medicines Agency and one approval through the UK MHRA.
In the UK, Aurobindo Pharma's subsidiary CuraTeQ Biologics got marketing authorisation for Dazublys, its biosimilar version of trastuzumab.
It is used to treat certain types of breast and stomach cancers.
Muralidharan said that while operating in the European markets, pricing pressure, currency volatility, and dealing with multiple regulators are the major challenges.
He pointed out that out of the nine markets in Europe, where Aurobindo operates, it is among the top 10 in eight countries.
Apart from the UK, the company operates in France, Germany, Spain, Portugal, Italy, Netherlands, Belgium, Poland and Malta.
The company's CFO, Subramaniam Santhanam, told the news channel that it has paused investments in greenfield and brownfield projects, as they have long gestation periods.
Aurobindo is ramping up its existing investment to add shareholder value, he added.
The company has more than 30 plants, and it is trying to increase its capacities.
